Get the Daily Brief
Latest Biotech News
Pfizer’s sickle cell drug fails critical Phase 3 trial
Pfizer disclosed that its sickle cell disease candidate, inclacumab, failed to demonstrate a significant reduction in vaso-occlusive crises compared to placebo in a pivotal Phase 3 trial. This...
Hatteras Venture Partners closes $200M for early-stage biotech funds
Despite a challenging fundraising environment, Hatteras Venture Partners successfully closed two new funds totaling $200 million targeting seed and early-stage biotech companies. This injection of...
CUT&Tag method adjusted to reveal transcription factor binding
Researchers at the University of Cologne have optimized the CUT&Tag assay by lowering salt concentrations, enabling detection of transient transcription factor-DNA interactions previously masked....
Biopharma Financing Trends: Record Deals with Fewer IPOs
Biopharma deal activity in 2025 has surged to record levels, with $164 billion in transactions in the first seven months, reflecting robust mergers and financings despite a drought in IPOs....
Nanoparticle and nanomaterial innovations in therapy and energy
Recent advances spotlight titanate nanotubes enhancing lithium-ion battery anodes for energy storage, and biosilica nanoparticles offering protection against liver ischemia-reperfusion injury by...
Immunotherapy and cancer metabolic reprogramming insights
New studies elucidate mechanisms driving cancer immune responses and chemoresistance, including how regulatory T cells amplify pro-inflammatory Th17 cells via IL-2, metabolic rewiring by androgens...
Neonatal lung disease trials expand globally
Airway Therapeutics announced expansion of its Phase III trial of zelpultide alfa, a recombinant surfactant protein D analog, in preterm neonates with bronchopulmonary dysplasia. The multinational...
Reinstatement of childhood vaccine safety task force amid controversy
The U.S. Department of Health and Human Services has revived the Task Force on Safer Childhood Vaccines after nearly three decades of dormancy, prompted by a lawsuit from an anti-vaccine group...
FDA Gives Full Nod to Precigen’s Rare Disease Gene Therapy
The US FDA has remarkably granted full and accelerated approval to Precigen’s gene therapy Papzimeos for treating recurrent respiratory papillomatosis (RRP), a rare disease characterized by benign...
Pfizer’s Sickle Cell Drug Fails Phase 3 Trial
Pfizer announced the failure of its sickle cell disease candidate inclacumab in a Phase 3 clinical trial, where the drug did not demonstrate a statistically significant benefit over placebo. This...
Human Embryo Implantation Captured in 3D Real Time
Researchers at the Institute for Bioengineering of Catalonia, collaborating with Dexeus University Hospital, have for the first time visualized and recorded human embryo implantation in real time...
Breakthrough Cancer Drug Shows Promise in Clinical Trial
A recent clinical trial has highlighted a novel cancer drug with efficacy in eradicating aggressive tumors. The investigation focused on a CD40 agonist antibody, a class historically limited by...
Advances in Nanobody Therapy Target Lung Cancer
Scientists at the Korea Research Institute of Bioscience and Biotechnology have developed a cutting-edge nanobody-based therapeutic modality specifically targeting lung cancer cells. The approach...
New Insights into Immune Cell Interactions Shape Immunotherapy
Groundbreaking research reveals a complex interplay between regulatory T cells (Tregs) and pro-inflammatory Th17 cells mediated by a balance of cytokines including TGF-β, IL-6, and IL-2. This...
HHS Revives Childhood Vaccine Safety Task Force Amid Controversy
In a significant policy move, the US Department of Health and Human Services reinstated the Task Force on Safer Childhood Vaccines, disbanded since 1998. This action follows a lawsuit filed by the...
Kickstarting RNA Analysis: CUT&Tag Buffer Modification Unlocks New Capabilities
German researchers from the University of Cologne have optimized the CUT&Tag assay by reducing salt concentrations in buffers, overcoming prior limitations preventing measurement of transcription...
Major Investment Backs Gene Therapy Startup Kriya Therapeutics
Kriya Therapeutics, a biotech company focused on gene therapy, has secured a $313 million funding round, marking a significant financial boost for its development programs. Operating between North...
Biopharma Deal Volume Slows Despite Surge in Deal Value
The biopharmaceutical industry experienced a record-high surge in deal values totaling $164 billion in the first seven months of 2025, a 36% increase year-over-year. However, the total number of...
FDA Accelerates Rare Disease Gene Therapy Approval
The U.S. Food and Drug Administration has granted a rapid, full approval to Precigen Inc.'s gene therapy Papzimeos for recurrent respiratory papillomatosis (RRP), a rare disease causing benign...
Pfizer’s Sickle Cell Drug Stumbles in Late-Stage Trial
Pfizer's sickle cell therapy candidate inclacumab failed to demonstrate efficacy in a pivotal Phase 3 trial, according to recent announcements. This failure follows Pfizer's voluntary withdrawal...